All In Biotech

Drug Trial Radar · NCT03070392

Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma

A Phase II Randomized, Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Compared With Investigator Choice in HLA-A*0201 Positive Patients With Previously Untreated Advanced Uveal Melanoma

Last checked: Nov 20, 2026Latest source record: Oct 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 378 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

378

Actual

Start

Oct 16, 2017

Primary completion

Oct 13, 2020

Study completion Sep 17, 2025

Sponsor

Lead sponsor
Immunocore LtdIndustry
Sponsor type
Industry
First posted
Mar 3, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 99 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate the overall survival of HLA-A\*0201 positive adult patients with previously untreated advanced UM receiving IMCgp100 compared to Investigator's Choice of dacarbazine, ipilimumab, or pembrolizumab.

Conditions

  • Uveal Melanoma

Interventions

  • IMCgp100Biological

    IMCgp100 is to be administered at 20 mcg cycle 1 day1, then 30 mcg cycle 1 day 8, then 68 mcg cycle 1 day 15 and weekly thereafter by IV infusion over 15 minutes until confirmed disease progression or unacceptable toxicity

  • DacarbazineDrug

    Dacarbazine is to be administered at 1,000 mg/m2 of body surface area IV infusion every 3 weeks until disease progression or unacceptable toxicity

  • IpilimumabBiological

    Ipilimumab is to be administered at 3 mg/kg IV infusion over 90 minutes every 3 weeks for a total of 4 treatments

  • PembrolizumabBiological

    Pembrolizumab is to be administered at 2 mg/kg IV infusion up to a maximum of 200 mg administered Intravenously over 30 minutes every 3 weeks or 200 mg fixed dose administered intravenously every 3 weeks where approved locally until confirmed disease progression or unacceptable toxicity

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall SurvivalTime frame: From randomization to the data cut off date of 13-Oct-2020; median follow-up duration was 14.1 months.

Locations

57 sites in 14 countries. Site status is shown where the registry gives one.

  • UCLA Medical Center

    Los Angeles, California

  • The Angeles Clinic and Research Institute

    Los Angeles, California

  • Byers Eye Institute, Stanford University

    Palo Alto, California

  • California Pacific Medical Center

    San Francisco, California

  • University of Colorado

    Aurora, Colorado

  • University of Miami - Sylvester Comprehensive Cancer Center

    Miami, Florida

  • Winship Cancer Institute of Emory University

    Atlanta, Georgia

  • Northwestern University

    Chicago, Illinois

  • The University of Chicago Medicine

    Chicago, Illinois

  • University of Iowa

    Iowa City, Iowa

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Dana Farber Cancer Institute

    Boston, Massachusetts

  • Washington University School of Medicine

    St Louis, Missouri

  • Roswell Park Cancer Institute

    Buffalo, New York

  • Columbia University Medical Center

    New York, New York

  • Memorial Sloan Kettering Cancer Center

    New York, New York

  • Duke University Health System

    Durham, North Carolina

  • The Ohio State University

    Columbus, Ohio

  • University of Oklahoma

    Oklahoma City, Oklahoma

  • Portland Providence Medical Center

    Portland, Oregon

  • Thomas Jefferson University Hospital

    Philadelphia, Pennsylvania

  • University of Pittsburgh Medical Center

    Pittsburgh, Pennsylvania

  • Houston Methodist Cancer Center

    Houston, Texas

  • Saint Vincents Hospital

    Darlinghurst, New South Wales, Australia

  • Central Adelaide Local Health Network, Royal Adelaide Hospital Cancer Center

    Adelaide, South Australia, Australia

  • Peter MacCallum Cancer Center

    Melbourne, Victoria, Australia

  • Institut Roi Albert II Cliniques Universitaires St-Luc

    Brussels, Belgium

  • Universite Catholique de Louvain Centre du Cancer, Medical Oncology

    Brussels, Belgium

  • Princess Margaret Cancer Centre

    Toronto, Canada

  • Cross Cancer Institute

    Edmonton, Alberta, Canada

  • Centre Atoine Lacassagne

    Nice, France

  • Institut Curie

    Paris, France

  • Charite - Campus Benjamin Franklin

    Berlin, Germany

  • Universitätsklinikum Carl Gustav Carus

    Dresden, Germany

  • University Hospital Essen

    Essen, Germany

  • University of Hamburg

    Hamburg, Germany

  • Nationales Centrum für Tumorerkrankungen

    Heidelberg, Germany

  • Klinik und Poliklinik für Dermatologie und Allergologie

    Munich, Germany

  • Universitaetsklinikum Koeln Dermatologie und Venerologie

    Cologne, North Rhine-Westphalia, Germany

  • Fondazione ICCRS

    Milan, Italy

Showing 40 of 57 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.